DDInter1010 DDInter1763
Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis. Impressively, ketorolac has a similar efficacy to standard doses of morphine and meperidine making it a useful opioid sparing agent.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Ketorolac {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Ketorolac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Ketorolac {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Ketorolac {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Ketorolac {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Ketorolac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is associated with {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Temsirolimus
Ketorolac {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Ketorolac {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Ketorolac {u} (Compound) resembles {v} (Compound) Fenbufen
Fenbufen {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Ketorolac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) KIAA0355
KIAA0355 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Ketorolac may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Ketorolac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Temsirolimus (Compound)
Ketorolac (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Temsirolimus (Compound)
Ketorolac (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Temsirolimus (Compound)
Ketorolac may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Ketorolac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is associated with kidney cancer (Disease) and kidney cancer (Disease) is treated by Temsirolimus (Compound)
Ketorolac (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Tacrolimus (Compound) and Tacrolimus (Compound) resembles Temsirolimus (Compound)
Ketorolac (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Tacrolimus (Compound) and Tacrolimus (Compound) resembles Temsirolimus (Compound)
Ketorolac (Compound) resembles Fenbufen (Compound) and Fenbufen (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Temsirolimus (Compound)
Ketorolac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is regulated by KIAA0355 (Gene) and KIAA0355 (Gene) is upregulated by Temsirolimus (Compound)